Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.

Liu, Tong; Liu, Duo; Jin, Yao; Dong, Mei

Liu, Tong; Liu, Duo; Jin, Yao; Dong, Mei.

Liu T; Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.
Liu D; Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.
Jin Y; Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.
Dong M; Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.

Immunopharmacol Immunotoxicol ; 44(6): 809-815, 2022 Dec.

Article en En | MEDLINE | ID: mdl-35708278

Asunto(s)

Biosimilares Farmacéuticos; Neoplasias de la Mama; Humanos; Femenino; Biosimilares Farmacéuticos/efectos adversos; Neoplasias de la Mama/tratamiento farmacológico; Metaanálisis en Red; China

Palabras clave

Breast cancer; efficacy; herceptin; network meta-analysis; trastuzumab biosimilar

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Biosimilares Farmacéuticos Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Female / Humans País como asunto: Asia Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google